Femasys (NASDAQ:FEMY) Trading Up 4.5%

Femasys Inc. (NASDAQ:FEMY) shares rose 4.5% during trading on Friday . The stock traded as high as $1.32 and last traded at $1.29. Approximately 62,294 shares traded hands during mid-day trading, a decline of 89% from the average daily volume of 590,263 shares. The stock had previously closed at $1.24.

Analysts Set New Price Targets

A number of research firms have recently commented on FEMY. Jonestrading upped their price objective on shares of Femasys from $7.00 to $10.00 and gave the company a “buy” rating in a research note on Wednesday, March 20th. Chardan Capital reaffirmed a “buy” rating and set a $12.00 price target on shares of Femasys in a research report on Monday, April 1st. Finally, HC Wainwright lifted their price target on shares of Femasys from $10.00 to $12.00 and gave the company a “buy” rating in a report on Monday, April 1st.

Femasys Trading Up 4.5 %

The company has a quick ratio of 7.37, a current ratio of 7.59 and a debt-to-equity ratio of 0.24. The business has a fifty day moving average price of $1.60 and a 200 day moving average price of $1.23.

Femasys (NASDAQ:FEMY) last posted its earnings results on Thursday, March 28th. The company reported ($0.19) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.19). The firm had revenue of $0.21 million during the quarter, compared to the consensus estimate of $0.30 million. Femasys had a negative net margin of 1,329.10% and a negative return on equity of 105.47%. On average, equities analysts forecast that Femasys Inc. will post -0.88 earnings per share for the current fiscal year.

Institutional Trading of Femasys

A number of institutional investors have recently added to or reduced their stakes in FEMY. Clear Creek Financial Management LLC boosted its position in shares of Femasys by 30.6% in the first quarter. Clear Creek Financial Management LLC now owns 309,274 shares of the company’s stock worth $479,000 after buying an additional 72,505 shares during the period. Barclays PLC acquired a new position in Femasys during the 3rd quarter worth $295,000. Wealthspire Advisors LLC bought a new stake in shares of Femasys in the 3rd quarter worth about $84,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Femasys in the 3rd quarter valued at about $35,000. 65.27% of the stock is owned by hedge funds and other institutional investors.

Femasys Company Profile

Femasys Inc, a biomedical company, develops novel solutions for women's healthcare market in the United States and internationally. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.